Search for content, post, videos
Advertisement

Zelmic becomes part of CTR Group

Center for Translational Research (CTR) expands by acquiring Zelmic, the GMP-approved Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), specialized in development of topical and transdermal pharmaceutical formulations and drug delivery.

The acquisition further expands CTRs portfolio, within pharmaceutical, regulatory, and clinical development to the CTR group, the company states.

“The addition of Zelmic in our company group will enable us to offer a more integrated approach that will benefit our current and new customers. Zelmic share our vision regarding the importance of quality and high scientific knowledge combined with solid experiences in drug development. We already have a proven track record of excellent collaboration with the team at Zelmic, and I look forward to extending this further,” says Karin Meyer, CEO at CTR.

Advertisement

CTR’s responsive approach to clinical and pharmaceutical development aligns perfectly with Zelmic’s vision for continued growth, aiming to become the preferred Nordic partner for drug development.”

“We are truly thrilled to join this dynamic group,” says David Sagna, CEO Zelmic. “By integrating our specialized expertise in topical drug development with the broader pharmaceutical, regulatory, and clinical capabilities of the CTR group, we can offer our clients even more comprehensive and innovative solutions. CTR’s responsive approach to clinical and pharmaceutical development aligns perfectly with Zelmic’s vision for continued growth, aiming to become the preferred Nordic partner for drug development. I am very optimistic about our future and see great synergistic potential in continuing our journey.”

Photo of David Sagna and Karin Meyer

Advertisement